Key points are not available for this paper at this time.
The comprehensive analysis of multiple omics data significantly enhances the molecular classification of lung adenocarcinoma. Furthermore, AIDPI is a potential biomarker that predicts the prognosis of LUAD patients. NPC2 inhibits the progression of LUAD by suppressing the PI3K/AKT signaling pathway and enhancing the chemotherapy sensitivity to Ribociclib.
Li et al. (Fri,) studied this question.